Literature DB >> 20471070

Identification of TNF-related apoptosis-inducing ligand and other molecules that distinguish inflammatory from resident dendritic cells in patients with psoriasis.

Lisa C Zaba1, Judilyn Fuentes-Duculan, Narat John Eungdamrong, Leanne M Johnson-Huang, Kristine E Nograles, Traci R White, Katherine C Pierson, Tim Lentini, Mayte Suárez-Fariñas, Michelle A Lowes, James G Krueger.   

Abstract

BACKGROUND: Previous work has identified CD11c(+)CD1c(-) dendritic cells (DCs) as the major "inflammatory" dermal DC population in patients with psoriasis vulgaris and CD1c(+) DCs as the "resident" cutaneous DC population.
OBJECTIVE: We sought to further define molecular differences between these 2 myeloid dermal DC populations.
METHODS: Inflammatory and resident DCs were single-cell sorted from lesional skin biopsy specimens of patients with psoriasis, and the transcriptome of CD11c(+)CD1c(-) versus CD1c(+) DCs was determined. Results were confirmed with RT-PCR, flow cytometry, immunohistochemistry, and double-labeled immunofluorescence. Human keratinocytes were cultured for functional studies.
RESULTS: TNF-related apoptosis-inducing ligand (TRAIL), Toll-like receptors 1 and 2, S100A12/ENRAGE, CD32, and many other inflammatory products were differentially expressed in inflammatory DCs compared with resident DCs. Flow cytometry and immunofluorescence confirmed higher protein expression on CD1c(-) versus CD1c(+) DCs. TRAIL receptors, death receptor 4, and decoy receptor 2 were expressed in keratinocytes and dermal cells. In vitro culture of keratinocytes with TRAIL induced CCL20 chemokine.
CONCLUSIONS: CD11c(+)CD1c(-) inflammatory DCs in psoriatic lesional skin express a wide range of inflammatory molecules compared with skin-resident CD1c(+) DCs. Some molecules made by inflammatory DCs, including TRAIL, could have direct effects on keratinocytes or other skin cell types to promote disease pathogenesis. Copyright (c) 2010 American Academy of Allergy, Asthma & Immunology. Published by Mosby, Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20471070      PMCID: PMC2910451          DOI: 10.1016/j.jaci.2010.03.018

Source DB:  PubMed          Journal:  J Allergy Clin Immunol        ISSN: 0091-6749            Impact factor:   10.793


  33 in total

1.  What is principal component analysis?

Authors:  Markus Ringnér
Journal:  Nat Biotechnol       Date:  2008-03       Impact factor: 54.908

2.  Identification of cellular pathways of "type 1," Th17 T cells, and TNF- and inducible nitric oxide synthase-producing dendritic cells in autoimmune inflammation through pharmacogenomic study of cyclosporine A in psoriasis.

Authors:  Asifa S Haider; Michelle A Lowes; Mayte Suárez-Fariñas; Lisa C Zaba; Irma Cardinale; Artemis Khatcherian; Inna Novitskaya; Knut M Wittkowski; James G Krueger
Journal:  J Immunol       Date:  2008-02-01       Impact factor: 5.422

3.  Psoriasis vulgaris lesions contain discrete populations of Th1 and Th17 T cells.

Authors:  Michelle A Lowes; Toyoko Kikuchi; Judilyn Fuentes-Duculan; Irma Cardinale; Lisa C Zaba; Asifa S Haider; Edward P Bowman; James G Krueger
Journal:  J Invest Dermatol       Date:  2008-01-17       Impact factor: 8.551

4.  Effective treatment of psoriasis with etanercept is linked to suppression of IL-17 signaling, not immediate response TNF genes.

Authors:  Lisa C Zaba; Mayte Suárez-Fariñas; Judilyn Fuentes-Duculan; Kristine E Nograles; Emma Guttman-Yassky; Irma Cardinale; Michelle A Lowes; James G Krueger
Journal:  J Allergy Clin Immunol       Date:  2009-11       Impact factor: 10.793

5.  TRAIL stimulates proliferation of vascular smooth muscle cells via activation of NF-kappaB and induction of insulin-like growth factor-1 receptor.

Authors:  Mary M Kavurma; Michael Schoppet; Yuri V Bobryshev; Levon M Khachigian; Martin R Bennett
Journal:  J Biol Chem       Date:  2008-01-03       Impact factor: 5.157

Review 6.  Emerging role of tumour necrosis factor-related apoptosis-inducing ligand (TRAIL) as a key regulator of inflammatory responses.

Authors:  Adam Collison; Paul S Foster; Joerg Mattes
Journal:  Clin Exp Pharmacol Physiol       Date:  2009-07-27       Impact factor: 2.557

7.  Normal human dermis contains distinct populations of CD11c+BDCA-1+ dendritic cells and CD163+FXIIIA+ macrophages.

Authors:  Lisa C Zaba; Judilyn Fuentes-Duculan; Ralph M Steinman; James G Krueger; Michelle A Lowes
Journal:  J Clin Invest       Date:  2007-09       Impact factor: 14.808

8.  Lipoproteins of Listeria monocytogenes are critical for virulence and TLR2-mediated immune activation.

Authors:  Silke Machata; Svetlin Tchatalbachev; Walid Mohamed; Lothar Jänsch; Torsten Hain; Trinad Chakraborty
Journal:  J Immunol       Date:  2008-08-01       Impact factor: 5.422

9.  Critical link between TRAIL and CCL20 for the activation of TH2 cells and the expression of allergic airway disease.

Authors:  Markus Weckmann; Adam Collison; Jodie L Simpson; Matthias V Kopp; Peter A B Wark; Mark J Smyth; Hideo Yagita; Klaus I Matthaei; Nicole Hansbro; Bruce Whitehead; Peter G Gibson; Paul S Foster; Joerg Mattes
Journal:  Nat Med       Date:  2007-10-14       Impact factor: 53.440

10.  Amelioration of epidermal hyperplasia by TNF inhibition is associated with reduced Th17 responses.

Authors:  Lisa C Zaba; Irma Cardinale; Patricia Gilleaudeau; Mary Sullivan-Whalen; Mayte Suárez-Fariñas; Mayte Suárez Fariñas; Judilyn Fuentes-Duculan; Inna Novitskaya; Artemis Khatcherian; Mark J Bluth; Michelle A Lowes; James G Krueger
Journal:  J Exp Med       Date:  2007-11-26       Impact factor: 14.307

View more
  37 in total

Review 1.  Protein-protein interaction modulators: advances, successes and remaining challenges.

Authors:  Lloyd Mabonga; Abidemi Paul Kappo
Journal:  Biophys Rev       Date:  2019-07-12

2.  Early tissue responses in psoriasis to the antitumour necrosis factor-α biologic etanercept suggest reduced interleukin-17 receptor expression and signalling.

Authors:  A Johnston; A M Guzman; W R Swindell; F Wang; S Kang; J E Gudjonsson
Journal:  Br J Dermatol       Date:  2014-06-24       Impact factor: 9.302

3.  Reversal of atopic dermatitis with narrow-band UVB phototherapy and biomarkers for therapeutic response.

Authors:  Suzanne Tintle; Avner Shemer; Mayte Suárez-Fariñas; Hideki Fujita; Patricia Gilleaudeau; Mary Sullivan-Whalen; Leanne Johnson-Huang; Andrea Chiricozzi; Irma Cardinale; Shenghui Duan; Anne Bowcock; James G Krueger; Emma Guttman-Yassky
Journal:  J Allergy Clin Immunol       Date:  2011-07-16       Impact factor: 10.793

Review 4.  The IL-23/T17 pathogenic axis in psoriasis is amplified by keratinocyte responses.

Authors:  Michelle A Lowes; Chris B Russell; David A Martin; Jennifer E Towne; James G Krueger
Journal:  Trends Immunol       Date:  2013-01-03       Impact factor: 16.687

5.  Resolved psoriasis lesions retain expression of a subset of disease-related genes.

Authors:  Mayte Suárez-Fariñas; Judilyn Fuentes-Duculan; Michelle A Lowes; James G Krueger
Journal:  J Invest Dermatol       Date:  2010-09-23       Impact factor: 8.551

Review 6.  Immunology of psoriasis.

Authors:  Michelle A Lowes; Mayte Suárez-Fariñas; James G Krueger
Journal:  Annu Rev Immunol       Date:  2014       Impact factor: 28.527

7.  Evaluation of the psoriasis transcriptome across different studies by gene set enrichment analysis (GSEA).

Authors:  Mayte Suárez-Fariñas; Michelle A Lowes; Lisa C Zaba; James G Krueger
Journal:  PLoS One       Date:  2010-04-20       Impact factor: 3.240

8.  Gene profiling of narrowband UVB-induced skin injury defines cellular and molecular innate immune responses.

Authors:  Milène Kennedy Crispin; Judilyn Fuentes-Duculan; Nicholas Gulati; Leanne M Johnson-Huang; Tim Lentini; Mary Sullivan-Whalen; Patricia Gilleaudeau; Inna Cueto; Mayte Suárez-Fariñas; Michelle A Lowes; James G Krueger
Journal:  J Invest Dermatol       Date:  2012-11-15       Impact factor: 8.551

9.  Signaling through purinergic receptors for ATP induces human cutaneous innate and adaptive Th17 responses: implications in the pathogenesis of psoriasis.

Authors:  Meaghan E Killeen; Laura Ferris; Erine A Kupetsky; Louis Falo; Alicia R Mathers
Journal:  J Immunol       Date:  2013-03-11       Impact factor: 5.422

Review 10.  Current and potential immune therapies and vaccines in the management of psoriasis.

Authors:  Benjamin H Kaffenberger; Grace L Lee; Kelly Tyler; Derek V Chan; Wael Jarjour; Maria E Ariza; Marshall V Williams; Henry K Wong
Journal:  Hum Vaccin Immunother       Date:  2014-02-03       Impact factor: 3.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.